BRIEF-AstraZeneca says asthma drug granted paediatric exclusivity in U.S.

* Says decision was based on evaluation of trials conducted

in children with asthma aged six up to 12 years in response to a

written request

Source text for Eikon:

Further company coverage:

(Bengaluru Newsroom)

Read more